What's hot

View all perspectives
What's Hot
Sleep asleep

Sleep Quality & Psoriatic Arthritis

For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.

Read more →

Ultrasound in PsA

Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study

Watch video →

Tapering TNFi in nonradiographic AxSpA

Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.

Watch video →

Sunday (Day 2): ACR 22 Daily Recap

ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.

Watch video →

Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression

Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)

Watch video →

Deucravacitinib in PsA

Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial

Watch video →

Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial

Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)

Watch video →

Best of ACR Day Two in PSA

Watch video →

PET CT Imaging to Define Risk of Progression from PSO to PsA

Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.

Watch video →

ACR22 Daily Recap: Saturday Recap

Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate. 

Watch video →
      RT @doctorRBC: Exciting development in Lupus!
      Change in urinary biomarkers (CD163 and MMR) better predictor than protei

      Robert B Chao, MD doctorRBC

      3 years 1 month ago
      Exciting development in Lupus! Change in urinary biomarkers (CD163 and MMR) better predictor than proteinuria for lupus nephritis treatment response. Larger longitudinal studies needed. Abs#0536 @RheumNow #ACR22 #ACRBest https://t.co/MLSWdl0xUo
      RT @RichardPAConway: Bandeira et al. When to look for cardiac involvement in IIM. Lung involvement and anti-SRP abs both

      Richard Conway RichardPAConway

      3 years 1 month ago
      Bandeira et al. When to look for cardiac involvement in IIM. Lung involvement and anti-SRP abs both ORs of >7 main warning signs @rheumnow #ACR22 Abstr#0171 https://t.co/02cKN23Ufq https://t.co/3NioXUwVPM
      RT @AkhilSoodMD: Pearl - ‘Three Useful Ophthalmologic Acronyms’ with Dr. John Stone

      KP- Keratic Precipitates
      PUK- P

      Akhil Sood MD AkhilSoodMD

      3 years 1 month ago
      Pearl - ‘Three Useful Ophthalmologic Acronyms’ with Dr. John Stone KP- Keratic Precipitates PUK- Peripheral Ulcerative Keratitis IOI- Idiopathic Orbital Inflammation Add PUK to the Rheum Emergencies. Seen in #RA and #AAV @RheumNow #ACR22 https://t.co/GUc9boY0WV
      RT @RichardPAConway: Yang et al. Incidence and risk factors for cutaneous lupus becoming SLE. 11.8% transitioned after 2

      Richard Conway RichardPAConway

      3 years 1 month ago
      Yang et al. Incidence and risk factors for cutaneous lupus becoming SLE. 11.8% transitioned after 20 years. Age<40 (HR 3.25), in first 10 years after skin lupus diagnosis, SCLE>DLE (HR 0.28)/others (HR 0.11) @rheumnow #ACR22 Abstr#0338 https://t.co/IxVS4mOveD https://t.co/3VeQ8WPQtU
      RT @uptoTate: Clinical pearl! Talk to your PsA pts about sleep. Abs 0387 shows circular relationship between sleep quali

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Clinical pearl! Talk to your PsA pts about sleep. Abs 0387 shows circular relationship between sleep quality, emotional disorders, and activity in these patients. Emotional factors more relevant than inflammatory factors on sleep quality. #ACR22 @RheumNow https://t.co/0p5hfNHM91 https://t.co/XrMTmsoMYR
      RT @RichardPAConway: Patel @NaomiRheumMD et al. Baseline GTI in GCA in GiACTA. Blood pressure and glucose tolerance bigg

      Richard Conway RichardPAConway

      3 years 1 month ago
      Patel @NaomiRheumMD et al. Baseline GTI in GCA in GiACTA. Blood pressure and glucose tolerance biggest contributors. Higher in relapsing 122.5 vs 98.9. BMI and neuropsych higher in relapsing. @rheumnow #ACR22 Abstr#0460 https://t.co/dSIt1xEOva https://t.co/2tAkgVEEeA
      RT @RichardPAConway: Patel @NaomiRheumMD et al. HbA1c in GiACTA. Tocilizumab assoc HbA1c reduction independent of steroi

      Richard Conway RichardPAConway

      3 years 1 month ago
      Patel @NaomiRheumMD et al. HbA1c in GiACTA. Tocilizumab assoc HbA1c reduction independent of steroids. Daily steroid dose assoc HbA1c @rheumnow #ACR22 Abstr#0461 https://t.co/9Nbewrpww8 https://t.co/NyeTyWICF6
      RT @uptoTate: Clinical pearl! Patient-reported treatment success in PsA assoc'd w/ control of arthritis, dactylitis, pso

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Clinical pearl! Patient-reported treatment success in PsA assoc'd w/ control of arthritis, dactylitis, psoriasis, and health-related QoL. Top 3 pt-reported reasons for tx failure were pain, psoriasis and fatigue. Abs0393 #ACR22 @RheumNow https://t.co/F9RNI7EXcL https://t.co/7DcLaqUqnm
      RT @RichardPAConway: Smith et al. MMF equally good if not better for Black vs White patients with SSc-ILD. Suggests wors

      Richard Conway RichardPAConway

      3 years 1 month ago
      Smith et al. MMF equally good if not better for Black vs White patients with SSc-ILD. Suggests worse outcomes for Black patients relate to more severe disease at presentation rather than treatment failure @RheumNow #ACR22 Abstr#0521 https://t.co/xZtAt6Kw1f https://t.co/f0jG9jsgQ7
      RT @RichardPAConway: Fukui et al. Retrospective study of alternate day steroids in IgG4-RD. No difference in flares. Sig

      Richard Conway RichardPAConway

      3 years 1 month ago
      Fukui et al. Retrospective study of alternate day steroids in IgG4-RD. No difference in flares. Significantly lower Glucocorticoid toxicity index -29.5 at 12 months -20 at 24 months. Not convinced until I see stronger data! @rheumnow #ACR22 Abstr#0128 https://t.co/20K4dKXE7R https://t.co/X4kJgCqhAE
      RT @RichardPAConway: Maguire et al @Sineadm15 @bososhea Stronger relationship between disease activity and QoL in men th

      Richard Conway RichardPAConway

      3 years 1 month ago
      Maguire et al @Sineadm15 @bososhea Stronger relationship between disease activity and QoL in men than women with AxSpA. Our current tools may be inadequate to fully evaluate women with AxSpA @rheumnow #ACR22 Abstr#0406 https://t.co/duHqO0DXh3 https://t.co/yRcFiNpujT
      RT @KDAO2011: Woody Palmer fasciitis? Think cancer (esp ovarian CA in women) #acr22 @rheumnow https://t.co/c6nCATfGxt

      TheDaoIndex KDAO2011

      3 years 1 month ago
      Woody Palmer fasciitis? Think cancer (esp ovarian CA in women) #acr22 @rheumnow https://t.co/c6nCATfGxt
      RT @doctorRBC: Tofactinib efficacy for treatment of ankylosing spondylitis comparable across different BMI's. Regardless

      Robert B Chao, MD doctorRBC

      3 years 1 month ago
      Tofactinib efficacy for treatment of ankylosing spondylitis comparable across different BMI's. Regardless of BMI, tofacitinib better than placebo. BMI <25: more AE and SAE Abs#0405 @RheumNow #ACR22 https://t.co/qs3U4mjUXD
      RT @doctorRBC: Rates of MACE and VTE with upadacitinib were infrequent and consistent with background rates in RA, PsA a

      Robert B Chao, MD doctorRBC

      3 years 1 month ago
      Rates of MACE and VTE with upadacitinib were infrequent and consistent with background rates in RA, PsA and AS patients. Factors associated with MACE/VTE: age>65, HTN, DM, smoking, history CV event/VTE Abs#0510 @RheumNow #ACR22 https://t.co/AjtJF0p3QK
      RT @AurelieRheumo: Do you consider ttmt successful? Question Christeen et al. asked to 100+ PsA pts. 1/3 pts said no, th

      Aurelie Najm AurelieRheumo

      3 years 1 month ago
      Do you consider ttmt successful? Question Christeen et al. asked to 100+ PsA pts. 1/3 pts said no, they had > TJC, > SJC, > Pso & > dactylitis. Failure also w/: pain 24%, pso 15%, fatigue 12% and < ability to be active 9%. https://t.co/dQseCNSDBS Abstr #0393 #ACR22 @Rheumnow https://t.co/kGlmscsKL7

      Podcasts

      • ACR2022 - Day 4 00:14:40
      • Monday ACR 2022 Daily Recap 00:37:20
      • ACR2022 - Day 3.3 00:34:23

      Catch up on Conference Podcasts

      ×